68Ga-DOTA肽与18F-DOPA PET用于评估神经内分泌肿瘤患者 - Suppr

Suppr

超能文献

68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.

作者信息

Ambrosini Valentina, Rubello Domenico, Nanni Cristina, Al-Nahhas Adil, Fanti Stefano

出版信息

Nucl Med Commun. 2008 May;29(5):415-7. doi: 10.1097/MNM.0b013e3282ffd70d.

DOI:10.1097/MNM.0b013e3282ffd70d

PMID:18391723

Abstract

摘要

相似文献

68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.

Nucl Med Commun. 2008 May;29(5):415-7. doi: 10.1097/MNM.0b013e3282ffd70d.

Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.

Clin Nucl Med. 2021 Mar 1;46(3):195-200. doi: 10.1097/RLU.0000000000003447.

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17.

68Ga-DOTA-peptides in the diagnosis of NET.

PET Clin. 2014 Jan;9(1):37-42. doi: 10.1016/j.cpet.2013.08.007. Epub 2013 Sep 14.

18F-DOPA PET/CT and neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2006 May;33(5):509-13. doi: 10.1007/s00259-006-0079-5.

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75.

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):765-70. doi: 10.1007/s00259-008-1030-8. Epub 2009 Jan 10.

Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):58-69. Epub 2015 Feb 12.

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.

Clin Nucl Med. 2021 Mar 1;46(3):181-186. doi: 10.1097/RLU.0000000000003450.

Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.

Br J Surg. 2010 May;97(5):691-7. doi: 10.1002/bjs.6937.

引用本文的文献

Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907. doi: 10.1007/s00259-013-2371-5. Epub 2013 Mar 5.

Nuclear medicine imaging of neuroendocrine tumours.

Clin Med (Lond). 2012 Aug;12(4):377-80. doi: 10.7861/clinmedicine.12-4-377.

⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S61-7. doi: 10.1007/s00259-011-1990-y.

Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.

J Endocrinol Invest. 2010 Jan;33(1):54-60. doi: 10.1007/BF03346550. Epub 2009 Oct 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.

作者信息

Ambrosini Valentina, Rubello Domenico, Nanni Cristina, Al-Nahhas Adil, Fanti Stefano

出版信息

Nucl Med Commun. 2008 May;29(5):415-7. doi: 10.1097/MNM.0b013e3282ffd70d.

DOI:10.1097/MNM.0b013e3282ffd70d

PMID:18391723

Abstract

摘要

相似文献

68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.

Nucl Med Commun. 2008 May;29(5):415-7. doi: 10.1097/MNM.0b013e3282ffd70d.

Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.

Clin Nucl Med. 2021 Mar 1;46(3):195-200. doi: 10.1097/RLU.0000000000003447.

Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8. doi: 10.1007/s00259-008-0769-2. Epub 2008 Apr 17.

68Ga-DOTA-peptides in the diagnosis of NET.

PET Clin. 2014 Jan;9(1):37-42. doi: 10.1016/j.cpet.2013.08.007. Epub 2013 Sep 14.

18F-DOPA PET/CT and neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2006 May;33(5):509-13. doi: 10.1007/s00259-006-0079-5.

Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75.

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):765-70. doi: 10.1007/s00259-008-1030-8. Epub 2009 Jan 10.

Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):58-69. Epub 2015 Feb 12.

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.

Clin Nucl Med. 2021 Mar 1;46(3):181-186. doi: 10.1097/RLU.0000000000003450.

Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.

Br J Surg. 2010 May;97(5):691-7. doi: 10.1002/bjs.6937.

引用本文的文献

Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907. doi: 10.1007/s00259-013-2371-5. Epub 2013 Mar 5.

Nuclear medicine imaging of neuroendocrine tumours.

Clin Med (Lond). 2012 Aug;12(4):377-80. doi: 10.7861/clinmedicine.12-4-377.

⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.

Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S61-7. doi: 10.1007/s00259-011-1990-y.

Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.

J Endocrinol Invest. 2010 Jan;33(1):54-60. doi: 10.1007/BF03346550. Epub 2009 Oct 9.